Dedicated to solving chronic inflammatory diseases
MIRIDITAS B.V. is a pharmaceutical company focused on developing a new class of anti‑inflammatory drugs for the treatment of chronic inflammatory diseases. Our team consists of specialized professionals working together to rapidly bring our groundbreaking solutions to the clinic.
Mission
Restoring vision, improving lives.
Miriditas B.V. was founded with the aim of developing safe, innovative treatments for chronic inflammatory diseases. With MIR001, we are targeting dry age-related macular degeneration, a global cause of vision loss for which no treatment currently exists. Our team consists of specialized professionals working together to rapidly bring groundbreaking solutions to the clinic
Meet Our Team
An innovative startup with unique expertise
Dr. Peter de Haan
Chief Executive Officer
Serial biotech entrepreneur (Founder of Viruvation, Amarna Therapeutics)
Virology, Gene therapy, Immunology and Patent expert
Dr. Ad van Gorp
Senior Advisor
Serial pharma entrepreneur (Founder Lead Pharma, Cytura Therapeutics, Saillant Therapeutics).
Protein Chemistry, Drug Development & Design expert
Dr. H ten Brink
Chief Project Officer
Serial program management positions (Sara Lee, Reckitt, Bevyz), COO at Noviocell.
Medical Chemistry, Drug Design & development